ASH: J&J's Darzalex cuts death risk by 40% in new myeloma patients

Johnson & Johnson hasn’t had problems convincing physicians to use multiple myeloma med Darzalex, which quickly went blockbuster and beyond on the back of some historic approvals. But new "gold standard" data presented Monday could further increase doctors’ confidence in the med, the company says.